Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia From the Randomized, Controlled, Double-Blind ASPECT-NP Trial

media

posted on 2020-09-28, 10:32 authored by Thomas Lodise, Joe Yang, Laura A. Puzniak, Ryan Dillon, Marin Kollef

<p>The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).<br></p> <p>© The authors, CC-BY-NC 2020.<b> </b></p>

History

Related Materials

1.
URL - References https://link.springer.com/article/10.1007/s40121-020-00343-0
2.
DOI - Is supplement to Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia From the Randomized, Controlled, Double-Blind ASPECT-NP Trial

Usage metrics

Infectious Diseases and Therapy

Categories

Keywords

Ceftolozane/tazobactam Hospital-acquired bacterial pneumonia Hospitalization Mechanical ventilation Meropenem Multidrug resistance Pseudomonas aeruginosa Ventilator-associated bacterial pneumonia

Licence

Exports